Post

New research · Endocrinology
Diabetes care · 4d
Cohort studyDiabetes care · 2026

Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study.

Victoria E L Milbourn, Ruth Barn, Zoë Tieges … Jaap J van Netten
Read paper
EndocrinologyCohort study

Most people with Charcot neuro-osteoarthropathy experience an emergency hospitalization.

Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study.

Victoria E L Milbourn … Jaap J van Netten
Diabetes care · 2026
Purpose

The aim for this study was to describe adverse outcomes after Charcot neuro-osteoarthropathy (charcot neuro-osteoarthropathy) diagnosis in adults with diabetes and examine variation by clinical and sociodemographic characteristics.

Methods

A regional, registry-based cohort study was conducted using linked routinely collected health care data from adults with diabetes and a first recorded charcot neuro-osteoarthropathy diagnosis in the National Health Service Greater Glasgow and Clyde, Scotland (2015-2024).

n = 127,513 adults
Results

most people with Charcot foot had an emergency hospitalization

HR by subgroup · 95% CI
null = 1
lower-extremity amputation
8.52
mortality rate
3.04
More results

From 127,513 adults with diabetes, 140 individuals with a first recorded charcot neuro-osteoarthropathy diagnosis were identified; their mean age was 59 years, and 67% were men.

The estimated 5-year survival was 67%, while 5-year amputation-free survival was 44% (median 4.04 years).

More results

Advanced chronic kidney disease (stages 4 and 5) was associated with higher risk across outcomes.

“
Conclusion · 1 of 2

Adverse outcomes in charcot neuro-osteoarthropathy were frequent and occurred early after diagnosis, with high rates of emergency hospitalization, amputation, and death.

Conclusion · 2 of 2

These findings support charcot neuro-osteoarthropathy as a marker of systemic vulnerability and highlight the need for prioritized surveillance and multidisciplinary management in routine clinical care.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Randomized Trial
MD: -0.98 μg/mL
the supplement combination significantly lowered systemic inflammation
Case Report
13/22
13 of the 22 neck glands removed were found to contain cancer
Review
43
most nutritional support statements for GLP-based therapies had expert agreement
Cross-sectional
43%
of people using automated insulin delivery, this many had poor sleep quality
Cohort Study
5.60
New-onset diabetes patients on insulin had 5.60 times higher hazard of pancreatic cancer.
Cohort Study
HR 4.0
Eyes with surgical complications during the transplant had about 4-fold higher risk of graft failure.
Cohort Study
OR 18.90
far higher odds of fatty-liver inflammation with scarring at the top blood-marker level
Review
30-37%
SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths